An interventional study of Angiomics AI-based Coronary CT Interpretation Tool and Standard CCTA Interpretation without AI in Chest Pain, Acute Coronary Syndrome and Coronary Artery Disease, sponsored by Yonsei University. Recruiting at 1 site in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Yonsei University · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Chest Pain with a site in Korea, Republic of — 3 open to participants now, 4 under way, none of them phase 3. Chest Pain · Korea, Republic of.
Among the 10 studies in Chest Pain with a site in Korea, Republic of, this one is one of 2 that started in 2025, is one of 9 with no phase, and was the 9th registered.
389 studies on the registry are indexed under Chest Pain; 65 are open to participants now.
Browse Chest Pain studies →3 of the 10 studies in Chest Pain with a site in Korea, Republic of are open now. Recruiting first, the newest first:
CHA University · Sites in Korea, Republic of
Ages 18+
Ewha Womans University Mokdong Hospital · Sites in Korea, Republic of
Ages 18+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 43 Chest Pain studies recruiting now, 30 (70%) set no upper age limit and 6 (14%) stop at 75 or younger; 5 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 620 is above the median of 128 across 205 interventional studies indexed under Chest Pain.
Median enrollment 681 across the 9 interventional studies, 8,814 across the 1 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 10 has an industry lead sponsor. The 7 most frequent:
Yonsei University is the lead sponsor of 1,421 studies on the registry; 241 are open to participants now.
Yonsei University has 1 study filed under Chest Pain — fewer than ten, so there is no comparison to draw.
1 of the studies in Chest Pain with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07235657Yonsei UniversityAI-Assisted Interpretation of Cardiac CT in the Emergency Department | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Chest Pain with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective, pragmatic, randomized controlled trial is designed to evaluate the impact of an artificial intelligence (AI)-based coronary computed tomography angiography (CCTA) interpretation tool (Angiomics) on emergency physicians' diagnostic performance and clinical decision-making in patients presenting with acute chest pain.
CCTA is a critical diagnostic modality for suspected acute coronary syndrome (ACS) in the emergency department (ED). Accurate interpretation often requires experienced radiologists, who may not always be available, particularly during off-hours. The introduction of AI-based interpretation tools into clinical workflow has the potential to enhance diagnostic accuracy, increase physician confidence, reduce delays in decision-making, and improve efficiency of resource utilization. However, evidence regarding the real-world effectiveness of such AI tools in the ED setting remains limited.
Eligible participants will include adults aged 18 years or older presenting to the ED with chest pain and classified as intermediate risk (HEART score 4-6). Participants will be randomized into two groups: (1) AI-assisted CCTA interpretation, in which emergency physicians interpret scans with access to AI results; and (2) standard interpretation, in which emergency physicians interpret CCTA without AI support. In both groups, physicians will document the presence of stenosis in the four major coronary arteries (LM, LAD, LCX, RCA).
After informed consent, participants are randomised in a 1:1 ratio before CCTA acquisition to AI-assisted or standard CCTA interpretation. Diagnostic confidence is recorded using four categories: very high, high, moderate and low. The enrolment target is 620 participants, with 310 participants per group. This is a single-centre trial conducted at Severance Hospital, Seoul, Republic of Korea.
The primary outcome is the negative predictive value (NPV) of CCTA interpretation at the patient level, comparing AI-assisted versus standard interpretations against the reference standard of blinded consensus readings by board-certified radiologists. Secondary outcomes include per-patient diagnostic performance (sensitivity, specificity, PPV and AUROC), per-vessel diagnostic performance, emergency physician diagnostic confidence and protocol deviation rate. Other outcomes include cardiology consultation rate and time to disposition decision.
Enrollment and follow-up will be conducted at Severance Hospital over a 24-month period following IRB approval. The results are expected to provide evidence for the clinical utility and effectiveness of AI-based CCTA interpretation in the ED and to guide integration of AI into emergency care in order to optimize patient outcomes and healthcare efficiency.
This study is a prospective, pragmatic, randomized controlled trial designed to evaluate the impact of an artificial intelligence (AI)-based coronary computed tomography angiography (CCTA) interpretation tool (Angiomics) on the diagnostic accuracy, confidence, and decision-making of emergency physicians in patients presenting with acute chest pain.
Background and Rationale CCTA is widely used in the emergency department (ED) for patients presenting with acute chest pain or suspected acute coronary syndrome (ACS). It provides rapid and precise visualization of the coronary arteries and assists emergency physicians in making time-sensitive clinical decisions. However, interpretation of CCTA requires specialized training and experience, which may not always be available, particularly during nights or in resource-limited settings. This limitation can delay diagnosis and treatment, potentially leading to adverse patient outcomes.
Recent advances in AI technology have enabled the development of automated tools capable of analyzing CCTA images and identifying clinically significant findings such as coronary artery stenosis and myocardial ischemia. These tools have the potential to support emergency physicians by improving diagnostic accuracy, reducing interpretation time, enhancing physician confidence, and optimizing the use of healthcare resources. Despite these advantages, the influence of AI-based interpretation on real-world ED clinical workflows and physician decision-making remains insufficiently studied.
The present trial is designed to address this knowledge gap by evaluating whether the integration of an AI-based CCTA interpretation tool improves emergency physician diagnostic performance and clinical confidence, and whether such improvements translate into more reliable decision-making in the ED.
Study Design This study will employ a prospective, pragmatic, randomized controlled design. Eligible participants will be adults aged 18 years or older presenting to the ED with chest pain and classified as intermediate risk according to the HEART score (4-6 points). Participants are randomised after informed consent and before CCTA acquisition. Allocation is 1:1 between the AI-assisted interpretation group and the standard interpretation group.
All physicians will evaluate stenosis in the four major coronary arteries (left main, left anterior descending [LAD], left circumflex [LCX], and right coronary artery [RCA]) and record their findings using a standardized format (Yes/No/Non-diagnostic/Other findings). Emergency physicians record diagnostic confidence using four categories: very high, high, moderate and low.
Reference Standard The reference standard for diagnostic performance will be the blinded consensus interpretation of board-certified radiologists specialized in thoracic imaging. Previous studies have demonstrated concordance of 98-99% between expert radiologist consensus and invasive coronary angiography, supporting the validity of this approach.
Outcomes The primary outcome is the negative predictive value (NPV) of CCTA interpretation at the patient level, comparing AI-assisted versus standard interpretations. Patient-level outcomes will be derived by aggregating findings across the four major coronary arteries.
Secondary outcomes include:
Reader Experience and Image Quality Emergency physician imaging training, prior CCTA interpretation experience and years of clinical experience are collected. Image quality is assessed by a radiologist blinded to AI outputs, emergency physician interpretations and allocation, and classified as Poor/Fair or Good/Excellent. These variables are considered in exploratory adjusted analyses.
Analysis Population and Preliminary Interpretation Exposure The primary analysis uses a modified intention-to-treat population, excluding participants whose emergency physician was exposed to a preliminary radiology interpretation before completing the study interpretation. AI processing failures remain in the assigned group. A sensitivity analysis includes participants with prior preliminary radiology exposure when both index and reference interpretations are available.
Sample Size and Statistical Analysis The original enrolment target was 552 participants, with 276 participants per group, allowing for 10% dropout. Following consultation with a statistician, the target was revised using a pooled negative diagnosis rate of 64.9% to obtain 181 negative interpretations per group. Allowing for 10% dropout, the required sample size was 181/(0.649 × 0.90), rounded up to 310 participants per group, for a total of 620 participants. The IRB approved the sample-size amendment on 20 July 2026. The persons responsible for the sample-size decision did not have access to group-specific interim results.
An interim analysis was conducted on 8 September 2026. Type I error is controlled using the prespecified O'Brien-Fleming alpha-spending approach, accounting for the actual information fraction.
Diagnostic performance (sensitivity, specificity, PPV, NPV, accuracy) will be compared using chi-square or Fisher's exact tests as appropriate. Agreement between physician and radiologist consensus readings will be assessed using Cohen's Kappa. All statistical tests will be two-sided.
Data Collection and Confidentiality Data will be collected within the routine clinical workflow and stored in a secure, de-identified format according to institutional policies and national privacy regulations. Only authorized investigators will have access to the data. Data will be stored for three years after study completion before secure disposal.
Safety and Monitoring This trial poses minimal risk to participants, as it involves no procedures outside of routine clinical care. No additional radiation, medications, or invasive interventions are introduced by study participation. The study principal investigator will monitor protocol adherence and data quality on an annual basis. The study is subject to continuing IRB review and institutional monitoring or audit in accordance with institutional procedures. The principal investigator is responsible for protocol adherence, data integrity and safety reporting.
Significance This study will provide evidence regarding the clinical utility of an AI-based CCTA interpretation tool in the ED. Findings are expected to clarify whether AI support improves diagnostic accuracy and physician confidence, and whether it can be effectively integrated into real-world emergency care. The results may inform best practices for the implementation of AI tools to optimize patient outcomes and resource utilization in acute care settings.
The criteria were revised on the registry on Nov 5, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adults aged 18 years or older Patients presenting to the emergency department with acute chest pain or chest discomfort Patients assessed as intermediate risk (Heart Score 4-6) Patients for whom CCTA was ordered by the treating physician as part of routine clinical care
Exclusion Criteria:
Prior history of coronary revascularization (coronary artery bypass graft surgery or stent placement) Presence of intracardiac metallic devices such as pacemaker or prosthetic heart valves to contrast media (e.g., contrast allergy, severe renal impairment with \< 30 mL/min/1.73 m²) Patients unable to cooperate (e.g., severe anxiety, non-cooperation) Non-diagnostic CCTA images are identified after image acquisition and handled according to the protocol-defined analysis exclusions.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Emergency physicians interpret coronary CT angiography (CCTA) with the assistance of an AI-based interpretation tool (Angiomics). Physicians record stenosis presence in four major coronary vessels and rate diagnostic confidence using a four-category confidence rating: very high, high, moderate and low.
Device: Angiomics AI-based Coronary CT Interpretation Tool
Emergency physicians independently interpret coronary CT angiography (CCTA) without access to the AI-based interpretation tool. Physicians record stenosis presence in four major coronary vessels and rate diagnostic confidence using a four-category confidence rating: very high, high, moderate and low.
Other: Standard CCTA Interpretation without AI
AI software integrated with the hospital PACS system to assist emergency physicians in interpreting coronary CT angiography (CCTA). The tool automatically analyzes stenosis in the left main, LAD, LCX, and RCA, and physicians use the results to guide their interpretation.
Emergency physicians independently interpret coronary CT angiography (CCTA) without access to the AI tool. Physicians evaluate stenosis in the left main, LAD, LCX, and RCA, and report diagnostic confidence using a four-category confidence rating: very high, high, moderate and low.
Per-patient negative predictive value of emergency physician CCTA interpretation
Negative predictive value is the number of true-negative patients divided by all patients classified as negative by the emergency physician, using blinded expert radiologist consensus as the reference standard. Significant coronary stenosis is defined as ≥50% luminal narrowing. A patient is classified as positive if at least one of the four major coronary vessels (LM, LAD, LCx or RCA) is positive, and as negative if all four vessels are negative. Negative predictive value is compared between the AI-assisted and standard interpretation groups.
Time frame: During the initial emergency department visit, at the time of index CCTA interpretation.
Per-patient diagnostic performance
Sensitivity, specificity, positive predictive value and area under the receiver operating characteristic curve of emergency physician interpretation, using blinded expert radiologist consensus as the reference standard. AUROC is calculated from binary stenosis classifications.
Time frame: During the initial emergency department visit, at the time of index CCTA interpretation.
Per-vessel diagnostic performance
Sensitivity, specificity, positive predictive value, negative predictive value and AUROC for the LM, LAD, LCx and RCA, using blinded expert radiologist consensus as the reference standard.
Time frame: During the initial emergency department visit, at the time of index CCTA interpretation.
Emergency physician diagnostic confidence
Distribution of four-category confidence ratings (very high, high, moderate and low), compared between randomised groups.
Time frame: At completion of the emergency physician's index CCTA interpretation during the initial emergency department visit.
Protocol deviation rate
Proportion of randomised participants with a documented protocol deviation.
Time frame: During the initial emergency department episode.
Cardiology consultation rate
Proportion of participants receiving cardiology consultation during the initial emergency department episode.
Time frame: During the initial emergency department episode.
Time to disposition decision
Elapsed time from emergency department arrival to the disposition decision.
Time frame: From emergency department arrival to the disposition decision during the initial emergency department episode.
Plan to share: Undecided — Requests for de-identified individual participant data, a data dictionary and analysis code will be considered after publication of the primary results. Access is subject to IRB approval and applicable confidentiality requirements.
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Jun 2027, 18 months after the start.
Of 85 non-industry interventional studies with no phase under Chest Pain, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 18 months is below that.
Counting every sponsor, half of 87 studies reached it within 23 months; a quarter within 9 and three quarters within 43.
Start moved once since we started tracking on Sep 25, 2026: Nov 2025 → Dec 2025, on Nov 5, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.